Concepedia

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Yoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda, Toshimi Takano, Toshiaki Saeki, Seigo Nakamura, Ryutaro Shimazaki, Yoshinori Ito, Yutaka Tokuda, Kazuo Tamura

Supportive Care in Cancer · 2015 · 99 citations · 15 references

Open access

Abstract

Pegfilgrastim is safe and significantly reduces the incidence of FN in breast cancer patients.

References

15

2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

Thomas J. Smith, James Khatcheressian, Gary H. Lyman et al. · Journal of Clinical Oncology · 2006 · 1.6K citations · Full text

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2006 · 537 citations · Full text

First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study

Charles L. Vogel, Marek Z. Wojtukiewicz, Robert R. Carroll et al. · Journal of Clinical Oncology · 2005 · 478 citations · Full text

Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study

Gary H. Lyman, David C. Dale, Jonathan W. Friedberg et al. · Journal of Clinical Oncology · 2004 · 312 citations · Full text

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

David R. Gandara, Tomoya Kawaguchi, John Crowley et al. · Journal of Clinical Oncology · 2009 · 213 citations · Full text